Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Appoints Cindy Perettie Executive Vice President of Kite
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces First Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD NRIX
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.